interim data analysis suggests ponatinib to be favorable tki treatment among cml patients
Published 3 years ago • 130 plays • Length 3:51Download video MP4
Download video MP3
Similar videos
-
7:47
is ponatinib safe for treating cml?
-
7:02
interim analysis from the optic trial, a dose-ranging study of ponatinib for cp-cml
-
3:31
ash 2021: new optic trial analysis shows ponatinib is effective in chronic myeloid leukemia patients
-
4:44
ponatinib in chronic-phase cml patients with prior second generation tki exposure
-
5:03
role of ponatinib in treatment of r/r cml
-
21:28
how nilotinib works and what to expect from it || nilotinib: benefits, side effects, and dosage
-
9:11
chronic myelogenous leukemia (updated 2023) - crash! medical review series
-
9:23
tasigna (nilotinib) side effects / cml treatment side effects / chronic myeloid leukemia
-
2:49
outcomes of patients with cml-cp treated with ponatinib vs 2g-tkis in the third-line setting
-
1:38
an update on the optic study: adjusting the dose of ponatinib for cp-cml
-
5:22
bosutinib versus ponatinib in r/r cml
-
1:16
ponatinib for cml and ph all: five-year results from the pace trial
-
5:58
what dose of ponatinib is both safe and effective to treat cml?
-
1:17
ponatinib versus ascimininib in the third-line treatment of cml
-
6:39
fda approves new dosing for ponatinib to treat chronic myeloid leukemia
-
24:30
management of thrombosis risk with ponatinib and other tkis for cml?
-
6:16
optic: a dose-ranging study of 3 starting doses of ponatinib for chronic-phase chronic myeloid l...
-
4:12
rationale for tki therapy in relapsed cml
-
2:20
dose modification of ponatinib in cp-cml: data from the pace and optic trials
-
2:51
the use of asciminib versus ponatinib for multiresistant cml
-
3:20
case 1: ponatinib in chronic-phase cml
-
1:21
next steps for ponatinib